Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A ...
Meeting tax deadlines is crucial, but good year-round habits — including making use of workplace benefits — can help lower ...
Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for ...
© 2026 Forbes Media LLC. All Rights Reserved.
CytomX Therapeutics Inc (CTMX) reports encouraging results from its Varseta-M study, with plans for a pivotal trial and expansion into new tumor types.
© 2026 Forbes Media LLC. All Rights Reserved.
Year-Over-Year Production Growth and Highest Annual Free Cash Flow Since 2021Receipt of New Drilling Permits Supports Planned 2026 Drilling ...
Bank of America has raised its Brent oil price forecast for 2026 as disruptions in the Strait of Hormuz tighten global supply ...
Back in 2024, Renesas first released the RA0E1, an ultra-low-power Cortex-M23 MCU designed for cost-sensitive applications, followed by the RA0E2, with ...
Investing.com -- Citi analysts have identified a group of oil and gas exploration and production companies positioned to ...
A criminal mastermind made sure their unusual poison attack would be fatal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results